Trial Profile
A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CALM
- Sponsors Viralytics
- 31 Aug 2021 Results published in the Journal of Clinical Oncology
- 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 20 Apr 2016 Results (extension study) assessing the impact of CVA21 on immune cell infiltrates and immune checkpoint molecules within treated lesions presented at the 107th Annual Meeting of the American Association for Cancer Research.